Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
Conclusion 4A6 is a novel specific inhibitor of the β5 subunit-associated chymotrypsin-like proteasome activity. Further exploration of 4A6 as a lead compound for development as a novel proteasome-targeted drug is warranted.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Investigational New Drugs | Leukemia | Multidrug Resistance | Study | Velcade